Sandoz to donate up to USD 10 million of high-quality generic medicines annually to Americares to increase access to medicines

Princeton, New Jersey, November 22, 2016. Sandoz today announced a collaboration to increase access to medicines by donating up to USD 10 million of stock annually to Americares, a health-focused relief and development organization that responds to people affected by poverty or disaster with life-changing health programs, medicine and medical supplies.

The initial donation will include over 25 Sandoz products for treatment for infections, cardiovascular conditions, eyecare, skin conditions and musculoskeletal pain. It is part of the global Sandoz commitment to …

/by

Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator

  • No clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks[1]
  • Innovative study design demonstrates switching between biosimilar etanercept and the originator product has no impact on safety and efficacy[1]
  • Sandoz biosimilar etanercept was approved by the FDA* in August 2016 and is currently under review by the EMA**

Holzkirchen, November 18, 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today …

/by